Bordetella pertussis strain variation and evolution postvaccination

Expert Review of Vaccines

Volumn 8, Issue 7, 2009, Pages 863-875

  Kallonen, Teemu ^a,b   He, Qiushui ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Bordetella pertussis; Evolution; Genotype; Microarray; Pertussis; Pulsed field gel electrophoresis; Serotype; Strain variation; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE;

ADOLESCENT; BACTERIAL GENOME; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; EPIDEMIC; GENE SEQUENCE; GENOTYPE; HUMAN; INCIDENCE; MOLECULAR EVOLUTION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SEQUENCE ANALYSIS; SEROTYPING; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; EUROPE; GENETIC VARIATION; HUMANS; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; VIRULENCE FACTORS; WHOOPING COUGH; YOUNG ADULT;

EID: 67650458490     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.46     Document Type: Review

References (88)

1. Pertussis (whooping cough). In: WHO-recommended standards for surveillance of selected vaccinepreventable diseases. WHO, Geneva, Switzerland (2003).
2. Halperin SA. The control of pertussis: 2007 and beyond. N. Engl. J. Med. 356(2), 110-113 (2007).
3. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 24(9), 761-765 (2005).
4. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg. Infect. Dis. 7(3 Suppl.), 526-528 (2001). (Pubitemid 32726822)
5. Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J. Pertussis in Poland. Int. J. Epidemiol. 33(2), 358-365 (2004).
6. Elomaa A, Advani A, Donnelly D et al. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J. Clin. Microbiol. 43(8), 3681-3687 (2005). (Pubitemid 41129646)
7. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J. 22(1), 22-27 (2003). (Pubitemid 36091773)
8. McIntyre P, Gidding H, Gilmour R et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun. Dis. Intell. (Suppl. i-xi), 1-111 (2002).
9. Lee YS, Yang CY, Lu CH, Tseng YH. Molecular epidemiology of Bordetella pertussis isolated in Taiwan, 1992-1997. Microbiol. Immunol. 47(12), 903-909 (2003).
10. Moerman L, Leventhal A, Slater PE, Anis E, Yishai R, Marva E. The reemergence of pertussis in Israel. Isr. Med. Assoc. J. 8(5), 308-311 (2006).
11. Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec. 80(4), 31-39 (2005).
12. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25(14), 2634-2642 (2007). (Pubitemid 46400927)
13. Parkhill J, Sebaihia M, Preston A et al. Comparative ana lysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35(1), 32-40 (2003). •• First description of annotated genome sequences of three 'classical' Bordetella species.
14. Caro V, Hot D, Guigon G et al. Temporal ana lysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microbes Infect. 8(8), 2228-2235 (2006). (Pubitemid 44322059)
15. Heikkinen E, Kallonen T, Saarinen L et al. Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS ONE 2(9), e904 (2007).
16. King AJ, van Gorkom T, Pennings JL et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics 9, 311 (2008).
17. Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 174-181 (2000). (Pubitemid 30201292)
18. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccinedriven evolution. Infect. Immun. 66(2), 670-675 (1998). •• First report of antigenic divergence between Dutch vaccine strains and circulating isolates. (Pubitemid 28074211)
19. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 67(6), 3133-3134 (1999). (Pubitemid 29244740)
20. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J. Infect. Dis. 182(5), 1402-1408 (2000).
21. Tsang RS, Lau AK, Sill ML et al. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42(11), 5364-5367 (2004). (Pubitemid 39506258)
22. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 39(12), 4396-4403 (2001). (Pubitemid 33117129)
23. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43(6), 2856-2865 (2005). • Systemic study of Swedish Bordatella pertussis isolates from three periods with different vaccination programs.
24. Caro V, Njamkepo E, Van Amersfoorth SC et al. Pulsed-field gel electrophoresis ana lysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect. 7(7-8), 976-982 (2005). • Comparative study of B. pertussis isolates in different European countries. (Pubitemid 40982664)
25. Schouls LM, van der Heide HG, Vauterin L, Vauterin P, Mooi FR. Multiple-locus variable-number tandem repeat ana lysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J. Bacteriol. 186(16), 5496-5505 (2004). • First evaluation of Dutch B. pertussis strains by multilocus variable number of tandem repeat ana lysis. (Pubitemid 39038152)
26. van Amersfoorth SC, Schouls LM, van der Heide HG et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol. 43(6), 2837-2843 (2005). • Comparative study of B. pertussis isolates in different European countries.
27. Elomaa A, Advani A, Donnelly D et al. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine 25(5), 918-926 (2007). (Pubitemid 44856120)
28. Bouchez V, Caro V, Levillain E, Guigon G, Guiso N. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS ONE 3(6), e2437 (2008).
29. Eldering G, Holwerda J, Davis A, Baker J. Bordetella pertussis serotypes in the United States. Appl. Microbiol. 18(4), 618-621 (1969).
30. Bronne-Shanbury C, Miller D, Standfast AF. The serotypes of Bordetella pertussis isolated in Great Britain between 1941 and 1968 and a comparison with the serotypes observed in other countries over this period. J. Hyg. (Lond.) 76(2), 265-275 (1976).
31. Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun. Dis. Rep. CDR Rev. 2(13), R152-R154 (1992).
32. Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to pertussis. Commun. Dis. Rep. CDR Rev. 2(13), R155-R156 (1992).
33. Van Loo IH, Mooi FR. Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology 148(Pt 7), 2011-2018 (2002). (Pubitemid 34785285)
34. Caro V, Elomaa A, Brun D, Mertsola J, He Q, Guiso N. Bordetella pertussis, Finland and France. Emerg. Infect. Dis. 12(6), 987-989 (2006).
35. Borisova O, Kombarova SY, Zakharova NS et al. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin. Vaccine Immunol. 14(3), 234-238 (2007). (Pubitemid 46570277)
36. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev. Vaccines 6(1), 47-56 (2007). (Pubitemid 46232480)
37. Preziosi MP, Yam A, Wassilak SG et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am. J. Epidemiol. 155(10), 891-896 (2002). (Pubitemid 34517844)
38. Njamkepo E, Cantinelli T, Guigon G, Guiso N. Genomic ana lysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes Infect. 10(14-15), 1582-1586 (2008). • Comparative study of B. pertussis isolates in low and high vaccine coverage areas.
39. van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40(6), 1994-2001 (2002).
40. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53(Pt 5), 355-365 (2004). (Pubitemid 38586500)
41. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 3, 329-339 (2008). • Recent review on pertussis epidemiology and B. pertussis strains variation.
42. Peppler MS, Kuny S, Nevesinjac A et al. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J. Clin. Microbiol. 41(7), 3344-3347 (2003).
43. Fingermann M, Fernandez J, Sisti F et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine 24(17), 3513-3521 (2006).
44. Lin YC, Yao SM, Yan JJ et al. Molecular epidemiology of Bordetella pertussis in Taiwan, 1993-2004: suggests one possible explanation for the outbreak of pertussis in 1997. Microbes Infect. 8(8), 2082-2087 (2006).
45. Kodama A, Kamachi K, Horiuchi Y, Konda T, Arakawa Y. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. J. Clin. Microbiol. 42(12), 5453-5457 (2004). (Pubitemid 39664319)
46. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20(3-4), 299-303 (2001). (Pubitemid 32973770)
47. Fiett J, Letowska I, Gniadkowski M, Hryniewicz W. The new strategy for allele identification of the genes coding for pertussis toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella pertussis. J. Microbiol. Methods 55(3), 651-666 (2003). (Pubitemid 37357216)
48. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69(9), 5520-5528 (2001). (Pubitemid 32786487)
49. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 132(2), 185-193 (2004). (Pubitemid 38444600)
50. Wang J, Yang Y, Li J et al. Infantile pertussis rediscovered in China. Emerg. Infect. Dis. 8(8), 859-861 (2002).
51. Mastrantonio P, Spigaglia P, van Oirschot H et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 145(Pt 8), 2069-2075 (1999). (Pubitemid 29396937)
52. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1(8369), 122-126 (1984). (Pubitemid 14217548)
53. Sato Y, Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J. Exp. Clin. Med. 13(Suppl.), 79-88 (1988).
54. Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev. Vaccines 4(2), 173-184 (2005). (Pubitemid 40525059)
55. Godfroid F, Denoel P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev. Vaccines 4(5), 757-778 (2005). (Pubitemid 41530598)
56. Guiso N, Boursaux-Eude C, Weber C et al. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 19(23-24), 3248-3252 (2001). (Pubitemid 32324054)
57. Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO. Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS 115(6), 736-742 (2007). (Pubitemid 46854991)
58. Advani A, Donnelly D, Gustafsson L, Hallander HO. Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. APMIS 115(4), 299-310 (2007).
59. Hallander H, Advani A, Riffelmann M et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J. Clin. Microbiol. 45(10), 3257-3262 (2007).
60. Hardwick TH, Cassiday P, Weyant RS, Bisgard KM, Sanden GN. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 8(1), 44-49 (2002).
61. van Loo IH, van der Heide HG, Nagelkerke NJ, Verhoef J, Mooi FR. Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J. Infect. Dis. 179(4), 915-923 (1999).
62. Caro V, Bouchez V, Guiso N, Gatti B, Agosti MR, Ayala SE. Pertussis in Argentina and France. Vaccine 25(22), 4335-4339 (2007).
63. Brinig MM, Cummings CA, Sanden GN, Stefanelli P, Lawrence A, Relman DA. Significant gene order and expression differences in Bordetella pertussis despite limited gene content variation. J. Bacteriol. 188(7), 2375-2382 (2006).
64. Heikkinen E, Xing DK, Olander RM et al. Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol. 8, 162 (2008).
65. Kasuga T, Nakase Y, Ukishima K, Takatsu K. Studies on Haemophilis pertussis. III. Some properties of each phase of H. pertussis. Kitasato Arch. Exp. Med. 27(3), 37-47 (1954).
66. Cummings CA, Brinig MM, Lepp PW, van de Pas S, Relman DA. Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J. Bacteriol. 186(5), 1484-1492 (2004). (Pubitemid 38248739)
67. Hot D, Antoine R, Renauld-Mongenie G et al. Differential modulation of Bordetella pertussis virulence genes as evidenced by DNA microarray ana lysis. Mol. Genet. Genomics 269(4), 475-486 (2003). (Pubitemid 36976155)
68. Maharjan RP, Gu C, Reeves PR, Sintchenko V, Gilbert GL, Lan R. Genome-wide ana lysis of single nucleotide polymorphisms in Bordetella pertussis using comparative genomic sequencing. Res. Microbiol. 159(9-10), 602-608 (2008).
69. Goyard S, Bellalou J, Mireau H, Ullmann A. Mutations in the Bordetella pertussis bvgS gene that confer altered expression of the fhaB gene in Escherichia coli. J. Bacteriol. 176(16), 5163-5166 (1994). (Pubitemid 24253764)
70. Fennelly NK, Sisti F, Higgins SC et al. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76(3), 1257-1266 (2008).
71. Tsang RS, Sill ML, Advani A, Xing D, Newland P, Hallander H. Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J. Clin. Microbiol. 43(5), 2449-2451 (2005). (Pubitemid 40656264)
72. van der Zee A, Vernooij S, Peeters M, van Embden J, Mooi FR. Dynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and post-vaccination strains and global distribution. Microbiology 142(Pt 12), 3479-3485 (1996). (Pubitemid 27026374)
73. Antila M, He Q, de Jong C et al. Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J. Med. Microbiol. 55(Pt 8), 1043-1051 (2006). (Pubitemid 44215562)
74. Advani A, Donnelly D, Hallander H. Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles. J. Clin. Microbiol. 42(7), 2890-2897 (2004). (Pubitemid 38938032)
75. Bottero D, Gaillard ME, Fingermann M et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome ana lysis of vaccine and clinical Bordetella pertussis strains. Clin. Vaccine Immunol. 14(11), 1490-1498 (2007). (Pubitemid 350304044)
76. Lee MS, Lee YS, Chiou CS. The suitable restriction enzymes for pulsed-field gel electrophoresis ana lysis of Bordetella pertussis. Diagn. Microbiol. Infect. Dis. 56(2), 217-219 (2006).
77. Boursaux-Eude C, Thiberge S, Carletti G, Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 17(20-21), 2651-2660 (1999). (Pubitemid 29314461)
78. Denoel P, Godfroid F, Guiso N, Hallander H, Poolman J. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 23(46-47), 5333-5341 (2005). (Pubitemid 41579303)
79. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccineinduced immunity against currently circulating B. pertussis isolates. Vaccine 22(17-18), 2122-2128 (2004).
80. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147(Pt 11), 2885-2895 (2001). (Pubitemid 33076978)
81. Hausman SZ, Burns DL. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun. 68(6), 3763-3767 (2000). (Pubitemid 30340490)
82. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J. 27(3), 218-223 (2008).
83. He Q, Makinen J, Berbers G et al. Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J. Infect. Dis. 187(8), 1200-1205 (2003). (Pubitemid 36438959)
84. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16(20), 1901-1906 (1998).
85. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916 (1998).
86. Hellwig SM, Rodriguez ME, Berbers GA, van de Winkel JG, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. 188(5), 738-742 (2003). (Pubitemid 37115187)
87. Aguas R, Goncalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect. Dis. 6(2), 112-117 (2006). (Pubitemid 43138909)
88. WHO (2007). Vaccine Preventable Diseases Monitoring System, global summary www.who.int/immunization-monitoring/ en/globalsummary/ countryprofileselect.cfm